Royalty Pharma(RPRX) ZACKS·2025-05-08 13:30Core Insights - Royalty Pharma (RPRX) reported quarterly earnings of $1.06 per share, exceeding the Zacks Consensus Estimate of $0.99 per share, and showing an increase from $0.98 per share a year ago, resulting in an earnings surprise of 7.07% [1] - The company achieved revenues of $839 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 5.72%, and up from $717 million in the same quarter last year [2] - Royalty Pharma's stock has increased by approximately 28.4% since the beginning of the year, contrasting with a decline of 4.3% in the S&P 500 [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $1.07, with expected revenues of $665.88 million, and for the current fiscal year, the EPS estimate is $4.44 on revenues of $2.97 billion [7] - The estimate revisions trend for Royalty Pharma is mixed, leading to a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Royalty Pharma belongs, is currently ranked in the top 33% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]